NSG
AVNS

Nalls Sherbakoff Group’s Avanos Medical AVNS Stock Holding History

Nalls Sherbakoff Group’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$2K Buy
+34
New +$1.78K ﹤0.01% 344

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nalls Sherbakoff Group's AVNS Position: Q4 2018 in Review

Nalls Sherbakoff Group opened a new position in Avanos Medical (AVNS) in Q4 2018: 34 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #344 among its holdings.

350 funds tracked by Wall St. Rank hold AVNS as of Q4 2018.

  • Nalls Sherbakoff Group held 34 shares of Avanos Medical worth $2K as of Q4 2018.
  • Avanos Medical was a new Nalls Sherbakoff Group position in Q4 2018.
  • Avanos Medical made up ﹤0.01% of Nalls Sherbakoff Group's portfolio in Q4 2018, its #344 holding.
  • 350 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2018.

Based on Nalls Sherbakoff Group's 13F filing for Q4 2018, filed 13 Feb 2019.